Hepatoma

26 registered clinical trials studyying Hepatoma — 2 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	MDN-001 Injection for the Treatment of Unresectable Primary Hepatocellular Carcinoma. NCT07391839	Suzhou Mednovo Yi Medical Technology Co., Ltd.	Phase 1
Not Yet Recruiting	The Diagnostic Efficacy and Lesion Detection Advantages of 18F-FDG PET/CT and Enhanced MRI in Hepatic Malignan NCT06700564	Shanghai East Hospital	—
Completed	A Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Liver Cancer Who Have Never NCT04567615	Bristol-Myers Squibb	Phase 2
Completed	Opioid Sparing Effect of Thoracic Epidural Analgesia for Open Upper Abdominal Surgery NCT04920019	Mahidol University	N/A
Completed	Combination of Regorafenib and Nivolumab in Unresectable Hepatocellular Carcinoma NCT04310709	Asan Medical Center	Phase 2
Unknown	Autologous CAR-T/TCR-T Cell Immunotherapy for Solid Malignancies NCT03941626	Shenzhen BinDeBio Ltd.	Phase 1 / Phase 2
Withdrawn	HepATocellular Cancer Hcv Therapy Study NCT04546802	Bayside Health	Phase 3
Unknown	Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies NCT03638206	Shenzhen BinDeBio Ltd.	Phase 1 / Phase 2
Terminated	TAE and MWA Combination Therapy in Early-stage Hepatocellular Carcinoma NCT02704130	Wake Forest University Health Sciences	N/A
Terminated	A Study of ONCO-DOX in Locally Advanced Hepatocellular Carcinoma NCT02460991	Boston Scientific Corporation	Phase 3
Withdrawn	Anesthetic Agents and Acute Kidney Injury After Liver Resection Surgery NCT02174575	Tokyo Medical and Dental University	Phase 4
Completed	Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Intravenous TKM-080301 in Subjects With Advanc NCT02191878	Arbutus Biopharma Corporation	Phase 1 / Phase 2
Withdrawn	Radiation Therapy With Sorafenib for TACE-Resistant Hepatocellular Carcinoma NCT01618253	Medical College of Wisconsin	Phase 1
Completed	Sorafenib and TRC105 in Hepatocellular Cancer NCT01306058	National Cancer Institute (NCI)	Phase 1 / Phase 2
Unknown	Study of Hepatoma Treated by Perfusing Cinobufacin Through Hepatic Artery Combining Embolotherapy NCT01236690	Changhai Hospital	Phase 2
Completed	IL-2 Expressing, Attenuated Salmonella Typhimurium in Unresectable Hepatic Spread NCT01099631	Masonic Cancer Center, University of Minnesota	Phase 1
Unknown	A Trial of EVL\GVS Alone vs. EVL\GVS Combined Propranolol NCT01298284	Taipei Veterans General Hospital, Taiwan	Phase 4
Terminated	Immunization With AFP + GM CSF Plasmid Prime and AFP Adenoviral Vector Boost in Patients With Hepatocellular C NCT00669136	Lisa H. Butterfield, Ph.D.	Phase 1
Completed	A Treatment of Unresectable Hepatocellular Carcinoma With TheraSphere® NCT00877136	St. Joseph Hospital of Orange	—
Completed	Study of Sorafenib and Transarterial Chemoembolization (TACE) to Treat Hepatocellular Carcinoma NCT00844883	Yale University	Phase 2
Completed	Safety of ON 01910.Na and Irinotecan or ON 01910.Na and Oxaliplatin in Patients With Hepatoma NCT00861783	Traws Pharma, Inc.	Phase 1
Terminated	Phase III Study of PI-88 in Post-resection Hepatocellular Carcinoma NCT00568308	Progen Pharmaceuticals	Phase 3
Completed	Trial of Beads Versus Doxorubicin Eluting Beads for Arterial Embolization of Hepatocellular Carcinoma NCT00539643	Memorial Sloan Kettering Cancer Center	Phase 2
Terminated	SIR-Spheres® for the Treatment of Unresectable Hepatocellular Carcinoma NCT00503867	Sirtex Medical	N/A
Completed	Radiolabeled Glass Beads Used for Treating Patients With Primary Liver Cancer When Surgery is Not an Option NCT00740753	OHSU Knight Cancer Institute	N/A
Unknown	Accuracy of Endoscopic Ultrasound for Detection of Tumors of the Liver NCT00290316	Central Texas Veterans Health Care System	Phase 2